Disease · MONDO_0005549

renal cell adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. renal cell adenocarcinoma. Diseases, record MONDO_0005549. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005549

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: renal cell adenocarcinoma; Open Targets
Open Targets ID: MONDO_0005549; Open Targets
Other names: RCC, adenocarcinoma of kidney, adenocarcinoma of the kidney, carcinoma, renal cell, malignant, kidney adenocarcinoma, renal cell cancer, renal cell carcinoma, renal cell carcinoma, stage unspecified; Open Targets
NCI Thesaurus: C9385; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 10 of its 89 drugs, from ClinicalTrials.gov; Open Targets

Drugs89

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 3	ClinicalTrials.gov	19	19	19	Drugs and targets
EVEROLIMUS	CHEMBL1908360	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
AXITINIB	CHEMBL1289926	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
SUNITINIB	CHEMBL535	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
SORAFENIB	CHEMBL1336	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
LENVATINIB	CHEMBL1289601	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
TIVOZANIB	CHEMBL1289494	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 89

See all 89 drugs

Targets202

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	13	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	11	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	11	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	9	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	8	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	7	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5156	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	5	Macrophage colony stimulating factor receptor antagonist; Macrophage colony stimulating factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/1436	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	5	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 3	https://conductscience.org/library/genes/2322	Drugs and targets
PDCD1	Programmed cell death protein 1	5	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
FGFR1	Fibroblast growth factor receptor	4	Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2260	Drugs and targets

1 to 10 of 202

See all 202 targets

Trials97

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02811861	Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma	Phase 3	1,069	2021-09-24	Renal Cell Carcinoma	EVEROLIMUS, LENVATINIB, PEMBROLIZUMAB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT00073307	Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer	Phase 3	903	2011-12-14	Carcinoma, Renal Cell	SORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT00678392	Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer	Phase 3	723	2012-03-27	Kidney Neoplasms	AXITINIB, SORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT00920816	Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer	Phase 3	492	2014-02-04	Kidney Neoplasms	AXITINIB	Its record names the disease	ClinicalTrials.gov
NCT02460224	Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.	Phase 1/2	490	2022-02-10	Advanced Solid Tumors	IERAMILIMAB, SPARTALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00730639	A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies	Phase 1	395	2016-04-15	Metastatic Castration-resistant Prostrate Cancer, Renal Cell Carcinoma, Metastatic Melanoma, Non-small Cell Lung Cancer	NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00267748	Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)	Phase 2	317	2011-09-05	Carcinoma, Renal Cell	SUNITINIB MALATE	Its record names the disease	ClinicalTrials.gov
NCT02737475	An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread	Phase 1/2	166	2022-01-25	Advanced Cancer	BMS-986178, IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00338884	Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer	Phase 2	120	2011-06-14	Carcinoma, Renal Cell	SUNITINIB MALATE	Its record names the disease	ClinicalTrials.gov
NCT01024920	Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.	Phase 2	99	2020-06-17	Carcinoma, Renal Cell	NINTEDANIB, SUNITINIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 97

See all 97 trials

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Axitinib 5 mg vs Sorafenib 400 mg: serious adverse events	146 of 359	127 of 355	714	NCT00678392	Trial comparisons
Nintedanib (BIBF 1120) vs Sunitinib: Number of Participants With Adverse Events Leading to Dose Reduction	16 of 64	8 of 32	96	NCT01024920	Trial comparisons
Nintedanib (BIBF 1120) vs Sunitinib: Number of Participants With Adverse Events Leading to Discontinuation of Trial Drug	11 of 64	5 of 32	96	NCT01024920	Trial comparisons
Nintedanib (BIBF 1120) vs Sunitinib: deaths from any cause	50 of 64	25 of 32	96	NCT01024920	Trial comparisons
Nintedanib (BIBF 1120) vs Sunitinib: Number of Participants With Adverse Events Requiring or Prolonging Hospitalisation	15 of 64	10 of 32	96	NCT01024920	Trial comparisons
Nintedanib (BIBF 1120) vs Sunitinib: serious adverse events	20 of 64	11 of 32	96	NCT01024920	Trial comparisons
Modified Regimen A (Cohort 1) vs Regimen A (Cohort 2): serious adverse events	3 of 11	1 of 6	17	NCT00709995	Trial comparisons
Metastatic Melanoma vs Other Metastatic Cancers: The Number of Participants With Adverse Events	2 of 2	9 of 9	11	NCT00393029	Trial comparisons
Metastatic Melanoma vs Other Metastatic Cancers: In Vivo Survival of T-cell Receptor (TCR) Gene-engineered Cells in Participants	2 of 2	9 of 9	11	NCT00393029	Trial comparisons
Metastatic Melanoma vs Other Metastatic Cancers: serious adverse events	0 of 2	0 of 9	11	NCT00393029	Trial comparisons

Papers from its trials98

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27191266	RESULT	1	PubMed
25895027	RESULT	1	PubMed
22959186	RESULT	1	PubMed
20651059	RESULT	1	PubMed
20399677	RESULT	1	PubMed
20085939	RESULT	1	PubMed
19850637	RESULT	1	PubMed
19757215	RESULT	1	PubMed
19487915	RESULT	1	PubMed
19451442	RESULT	1	PubMed

1 to 10 of 98

See all 98 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005549

GET https://conductscience.org/api/diseases/v1/MONDO_0005549/drugs?page=2

API reference For AI assistants